Monteris Medical Announces Publication of Position Statements on Laser Interstitial Heat Therapy | New

PLYMOUTH, Minnesota., September 23, 2021 / PRNewswire / – Monteris Medical today announced that position statements supporting the use of laser interstitial heat therapy (LITT) for people with brain tumors and drug-resistant epilepsy have been published by the American Association of Neurological Surgeons ( AANS), Congress of Neurological Surgeons (CNS) and American Society for Stereotaxic and Functional Neurosurgery (ASSFN). These joint position statements provide a summary of evidence-based best practice to guide healthcare providers on the use of guided magnetic resonance (MR) LITT in the management of selected patients who may benefit from the treatment. minimally invasive laser technology.

The position statement for epilepsy states that surgery (open resection or LITT) should be considered when there is evidence of disabling seizures despite the use of antiepileptic regimens, and there are well-defined and surgically accessible epileptogenic foci. The goal of surgery is to eliminate or reduce seizures in order to improve the patient’s quality of life and reduce or eliminate the burden of his disease.

For patients with brain tumors, the joint company statements indicate that LITT should be considered for the management of primary brain tumors (gliomas / glioblastoma), recurrent tumors, brain metastases and radiation necrosis. The position statement for brain tumors and radiation necrosis follows the recent inclusion of LITT in the National Comprehensive Cancer Network® (NCCN) guidelines in June 2021. The NCCN guidelines added MRI-guided LITT as a treatment option to their Central Nervous System Guidelines for Brain Tumor Surgery (BRAIN-B) for patients who are not surgical candidates (craniotomy or resection) with potential indications, including relapsed brain metastases and radionecrosis. .

“Laser ablation has played an increasing role in the multidisciplinary approach to the treatment of drug-resistant epilepsy patients in recent years and is supported by a growing body of clinical evidence,” said Dr. Joshua Rosenow, director of functional neurosurgery and professor of neurosurgery at Northwestern University in Chicago. “Societies’ recognition of the minimally invasive LITT indicates a distinct shift in the way we treat patients with epilepsy and brain tumors.”

Position statements also refer to LITT’s strong safety profile and its economic value to hospitals. Data published for LITT shows that most patients are likely to avoid an intensive care stay and the generally longer hospital stay associated with open surgical resection. Patients undergoing LITT have also demonstrated rapid recovery and low rates of head pain, infection, complications, and readmission.

“This is truly a historic day for the patients and physicians we serve to have MRI-guided laser ablation recognized by leading neurosurgery companies as an evidence-based alternative for the appropriate patients,” said Martin J. Emerson, President and CEO of Monteris Medical. “Inclusion in clinical guidelines, upcoming Category I CPT® codes and expansion of coverage with major health insurance providers will provide patients with better access to this life-changing technology. “

About Monteris and the NeuroBlate System

Monteris Medical is a private company that develops and markets innovative MRI-guided ablation systems for performing minimally invasive and robot-controlled brain surgery, commonly known as laser ablation, LITT (Laser Interstitial Thermal Therapy) or SLA (Stereotactic Laser Ablation). ). The Monteris NeuroBlate System is the only minimally invasive system that enables a robotic interface for the precise and safe delivery of laser energy. The NeuroBlate device is a surgical tool and is not a treatment for a specific condition or condition. The Monteris Medical NeuroBlate System is indicated for the ablation, necrosis or coagulation of intracranial soft tissues, including brain structures (p. Current investors include Birchview Capital, Versant Ventures, SightLine Partners and BDC Capital.

Previous Global Endovenous Laser Ablation Market 2021 Top Player, Demand, Revenue, Statistics, Business Growth Analysis 2027 - Bulk Solids Handling
Next Lucid Diagnostics, a subsidiary of PAVmed, files a registration statement for an initial public offering | Business

No Comment

Leave a reply

Your email address will not be published.